Comparative bioequivalence study of the Naproxen 500 mg Delayed- Release tablets manufactured by Daana Pharma Company vs Naprosyn® tablets manufactured by Recipharm Pharmaceutical Company in healthy volunteers.

Start Date25 Dec 2024

Sponsor / Collaborator

Daana Pharmaceutical Co.

NCT06511973

/ CompletedPhase 1

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of BAY H006689, Naproxen 10% Topical Gel in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Researchers are looking for a better way to treat muscle and joint pains. Researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. However, recent studies have found that using these medications on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medication is applied.
BAYH006689 topical gel is under development for the treatment of muscle and joint pains.
In this study, participants will be healthy and will not benefit from BAYH006689. However, the study will provide information about how to test BAYH006689 in future studies with people who have muscle and joint pain.
The main purpose of this study is to check whether BAYH006689 topical gel causes any irritation to the skin in healthy participants using a patch test called cumulative irritant patch test design. To do this, researchers will apply gel to participants' skin once a day for 21 days. Skin reactions will be assessed using a scale which will provide a score for redness, swelling, and other signs of skin irritation.
In this study, researchers will randomly assign 4 sites adjacent to each other, on the back of the participants' bodies just below the shoulder blades.
The following treatment gels will be applied using a patch.
* BAYH006689
* Placebo, which looks like the study drug, but does not have any medicine in it.
* 0.2% sodium lauryl sulfate (is a common ingredient in personal care products and when in contact with skin it could cause some skin irritation)
* 0.9% saline
Each participant will be in this study for 22 days, which includes:
* a visit to the clinic within 21 days of the study start, to confirm if the participant can take part in the study.
* participants will receive their assigned treatment gels at the identified skin site for 21 days.
* an end of study visit on Day 22, during which the researchers will remove the designed patches and assess any signs of skin irritation.
During the study, the doctors and their study team will:
* do physical examinations
* check participants' health by performing urine tests
* ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Start Date23 Jul 2024

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Naproxen

100 Translational Medicine associated with Naproxen

100 Patents (Medical) associated with Naproxen

6,797

Literatures (Medical) associated with Naproxen

01 Feb 2025·International Journal of Pharmaceutics

Long-acting injectable in situ forming implants: Impact of polymer attributes and API

Article

Author: Burgess, Diane J ; Roy, Mckenzie ; Kwok, Owen ; Wang, Xiaoyi ; Wang, Ruifeng

Poly(DL-lactide-co-glycolide) (PLGA) and N-methyl-2-pyrrolidone (NMP)-based in situ forming implants are liquid formulations that solidify through phase separation following injection into the body. Drug is dissolved or suspended in the final formulation liquid prior to injection. Depending on the polymers used, the depots formed can deliver drug over different periods of time. Accordingly, it is important to understand the impact of PLGA properties on implant drug release. However, currently available publications only investigate such impacts based on a single drug, which is insufficient to determine the potential interplay between drug and PLGA properties affecting drug release, or to draw any solid conclusions concerning the general impact of PLGA on drug release. The current work explores in situ forming implants with different active pharmaceutical ingredients (APIs) to determine whether any interplay between the APIs and the polymer attributes might affect drug release. In particular, the drug state (solution or suspension form) may impact polymer interaction and drug release. Naproxen and meloxicam were chosen as model drugs and were loaded into in situ forming implants. The final implants of naproxen and meloxicam were solutions and suspensions, respectively. The impact of PLGA properties (slight changes in molecular weight (MW), slight/major changes in lactic/glycolic acid (L/G) ratio, as well as changes in polymer blockiness in end-cap (acid vs ester)) on drug release was investigated. The slight changes in PLGA MW (18-31 KDa), L/G ratio (75/15-85/15) and blockiness had similar impacts on the release of naproxen and meloxicam from the formulations. These impacts were consistent with a previous report on risperidone implants. However, the impact of end-cap and significant change in the L/G ratio (from 75/15-85/15 to 50/50) was determined to be drug dependent. For meloxicam and for risperidone (previous report), the ester end-cap (compared to the acid end-cap) and much higher L/G ratio (75/15-85/15 versus 50/50) resulted in significantly longer overall drug release durations. In contrast, the naproxen implants had shorter release durations when prepared with the ester end-caped polymer (compared to acid end-cap), and when prepared with significantly higher L/G ratio polymers (75/15-85/15 versus 50/50). In addition, using the same PLGA polymer, implants loading different APIs demonstrated different release durations. This work highlights the complexity of PLGA attributes in determining the performance of implant drug formulations and the critical role of the interplay with the API properties. This study provides valuable knowledge for the future development of in situ forming implant drug products.

01 Feb 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

A simple eco-friendly spectrofluorimetric resolution approach for the simultaneous determination of Naproxen and Domperidone in pharmaceutical formulation and human plasma; assessment of method greenness

Article

Author: Abdel Rahman, Mona A. ; Abdel Rahman, Mona A ; Ayish, Nada S. ; Ayish, Nada S ; Mostafa, Noha S ; Mostafa, Noha S.

Designing new verified methods for the determination of pharmaceutical compounds in their specified formulation without prior separation and with high sensitivity taking in consideration analytical performance and simplicity has become a major concern of pharmaceutical quality control units. In the present work, a new simple and eco-friendly spectrofluorimetric method was developed and validated for the determination of Naproxen (NAP) and Domperidone (DOM) in their binary mixture, pharmaceutical formulation in addition to human plasma without prior separation. The proposed method is based on measuring the second derivative fluorescence intensity for NAP at 345 nm and for DOM at 292 after excitation at 235 nm without any interference from each other. All the variables affecting fluorescence intensity were studied and optimized. The proposed method showed excellent sensitivity with limit of detection (LOD) 12.286 ng/mL and 3.240 ng/mL for NAP and DOM respectively. In compliance with the ICH requirements, the optimized method was validated and was successfully utilized for the determination of both drugs in their pharmaceutical formulation and human plasma. Finally, the greenness of the proposed method was assessed using different assessment tools.

01 Feb 2025·Journal of Hazardous Materials

Selected emerging contaminants in water: Global occurrence, existing treatment technologies, regulations and associated risk

Review

Author: Swami, Deepak ; Meena, Vinay ; Joshi, Nitin ; Chandel, Aman ; Prasher, Shiv O

Emerging contaminants (ECs) in aquatic environments have recently attracted the attention of researchers due to their ubiquitous occurrence and the potential risk they may pose to life. While advance analytical methods have improved global reporting in water matrices, additional information is needed to compile data on their occurrence, existing legislation, treatment technologies and associated human health risks. Therefore, the present study provides an overview of the occurrence of selected ECs, including personal care product, antibiotics, NSAIDs, EDCs and psychiatric drugs, the existing regulatory framework and their toxicological effects on human health. The water matrices under review are the treated wastewater, surface water, groundwater and, in a few cases, drinking water. The study also highlights different treatment technologies available, and evaluates their performance based on the removal efficiency for different classes of ECs. For removal of almost all ECs considered, ozonation integrated with gamma radiation was reported highly efficient. Risk analysis was also performed for selected ECs including diclofenac, ibuprofen, naproxen, carbamazepine, estrone, 17 β-estradiol, bisphenol A, sulfamethoxazole, erythromycin and triclosan. The human health risk analysis indicated the highest number of locations with potential risk due to the EDCs, with South America, Europe and Asia having multiple risks due to estrone and Bisphenol A. The results of this study will give a better insight into the current situation of ECs in the global water matrices, the performance assessment of treatment technologies and the risk analysis will describe the need for more robust regulatory structures around the world to prevent the occurrence of such contaminants in the aquatic environment.

News (Medical) associated with Naproxen

18 Nov 2024

·www.drugs.com

Certain Painkillers Can Raise Bleeding Risks for People on Blood Thinners

MONDAY, Nov. 18, 2024 -- People on blood thinners have a doubled risk of dangerous internal bleeding if they also take a non-steroidal anti-inflammatory drug (NSAID) like ibuprofen or naproxen, a new study warns. People typically are prescribed blood thinners to treat or prevent strokes , heart attacks, or blood clots in the legs or lungs, researchers said. NSAIDs also are known to thin the blood, and the new study shows that they can increase risk of uncontrolled bleeding in the gut, brain, lungs and bladder if taken alongside a blood thinner. “We found that for patients taking blood thinners for blood clots in the legs or lungs, using NSAIDs doubled the risk of bleeding compared with not using NSAIDs,” said researcher Soren Riis Peterson , a medical student with Aarhus University Hospital in Denmark. “The increased bleeding risk associated with NSAID use was not limited to the digestive tract but also seemed to affect other organ systems.” For the study, researchers analyzed data on nearly 52,000 Danish patients prescribed a blood thinner to treat a blood clot between 2012 and 2022. In Denmark, the NSAIDs diclofenac and naproxen can only be obtained through a prescription. This allowed researchers to track the health of patients who had been prescribed both a blood thinner and an NSAID. Overall, the risk of a bleed was two times higher when people took a blood thinner and an NSAID, compared to just taking a blood thinner, researchers found. The specific risk was four times higher for naproxen, three times higher for diclofenac and nearly twice as high for ibuprofen. Specific bleed risks included: Using NSAIDs with a blood thinner also tripled a person’s risk of anemia, researchers found. The pattern of risk remained similar across a wide variety of blood thinners, including rivaroxaban , apixaban , dabigatran , edoxaban and warfarin , results show. The new study was published Nov. 17 in the European Heart Journal . “For people taking blood thinners for blood clots in their legs or lungs, our research highlights the importance of being cautious when considering NSAIDs for pain or inflammation,” Petersen concluded in a journal news release. “We recommend that patients consult their doctor before taking NSAIDs along with a blood thinner.” In an accompanying editorial, Dr. Robert Storey , a professor of clinical cardiology with the University of Sheffield in the U.K., noted that NSAIDs are widely used, making up about 8% of prescriptions worldwide and often available over-the-counter. “It seems clear that avoiding NSAIDs in combination with [blood thinners] is the safest strategy to avoid excess bleeding risk,” Storey wrote. “However, if this is not possible, what mitigation can be put in place? NSAID prescription should obviously be at the lowest dose and for the shortest time possible, but choice of agent and route may also be important.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA

18 Nov 2024

·www.drugs.com

Bleeding Risk Increased With NSAID Use for VTE Patients Receiving Anticoagulants

MONDAY, Nov. 18, 2024 -- Patients with venous thromboembolism (VTE) initiating oral anticoagulants have an increased risk for bleeding when using nonsteroidal anti-inflammatory drugs (NSAIDs), according to a study published online Nov. 17 in the European Heart Journal . Søren Riis Petersen, from Aarhus University Hospital in Denmark, and colleagues conducted a nationwide cohort study of 51,794 VTE patients initiating oral anticoagulants between Jan. 1, 2012, and Dec. 31, 2022. Adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes were computed. The researchers found that the event rates for any bleeding per 100 person-years were 3.5 and 6.3 during periods without and with NSAID use, respectively (number needed to harm, 36 patients treated for one year). The adjusted hazard ratios for any bleeding associated with NSAID use versus nonuse were 2.09, 1.79, 3.30, and 4.10 overall, for ibuprofen, for diclofenac, and for naproxen, respectively. The adjusted hazard ratios associated with NSAID use versus nonuse were 2.24, 3.22, 1.36, 1.57, and 2.99 for gastrointestinal bleeding, intracranial bleeding, thoracic and respiratory tract bleeding, urinary tract bleeding, and anemia caused by bleeding, respectively. For anticoagulant and VTE subtypes, the results were consistent. "The common use of NSAIDs in patients with cardiovascular disease emphasizes the importance of being aware of the bleeding risks associated with their use," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHA

13 Nov 2024

·www.globenewswire.com

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

ART26.12, the Company’s Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain StudiesSOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, announced new data being presented today on ART26.12, Artelo’s lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, in osteoarthritis (OA) pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium in New York. This evidence adds OA pain to the list of pain types such as neuropathic and cancer bone pain where ART26.12 has shown potential as an analgesic with a novel mechanism of action. In this new research conducted at Stony Brook University, ART26.12 demonstrated more responsive symptom relief in a surgical rodent OA model than naproxen, a commonly used nonsteroidal anti-inflammatory drug (NSAID) in the treatment of OA. ART26.12 significantly improved weight-bearing on affected limbs at all three doses studied, indicating a reduction in OA-induced pain. Importantly, ART26.12 demonstrated a clear dose-response relationship, with higher concentrations yielding greater pain relief and more rapid responses than naproxen. The study, entitled “Fatty Acid Binding Protein 5 Inhibitor, ART26.12, is a Novel Analgesic for Osteoarthritis Pain,” was conducted by the Department of Orthopedics and Rehabilitation and the Department of Anesthesiology at the Renaissance School of Medicine at Stony Brook University by Drs. Kai Bou, Adam Bruzzese, Kaitlin Farrell, Chris Gordon, David Komatsu and Martin Kaczocha. “We are encouraged by these behavioral data showing efficacy for ART26.12 in alleviating osteoarthritis pain,” said Dr. Komatsu of Stony Brook University. “Furthermore, we are dedicated to completing our remaining analyses to gain a comprehensive understanding of the biological response to this promising compound.” According to the World Health Organization, OA affects over 500 million people globally. Symptoms of OA include joint debilitation and persistent, extreme pain. Artelo’s research continues with a focus on long-term efficacy, currently evaluating the effects of four weeks of repeated dosing of ART26.12 on pain behaviors as well as knee structures and joint degradation. ART26.12 operates through a novel lipid-signaling pathway by inhibiting FABP5, which reduces cytokine and chemokine expression linked to OA pain. Preclinical efficacy has already been seen in both single and repeat dosing scenarios suggesting potential for both acute and chronic OA pain management. Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, added, “This new OA research constitutes our seventh preclinical study in pain, all of which show ART26.12’s potential as an innovative alternative to NSAIDs and opioids for some of the most severe pain management challenges.” The U.S. Food and Drug Administration (FDA) cleared ART26.12 to initiate for its first-in-human Phase 1 single ascending dose study with initial results anticipated during the first half of 2025. As previously reported, ART26.12 has also been accepted into the NIH Helping to End Addiction Long Term Initiative’s Preclinical Screening Platform for Pain which seeks to accelerate development of non-opioid, non-addictive treatment options for pain management. About ART26.12 ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) cleared by the FDA to initiate first-in-human studies, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN). Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio. About Stony Brook University Stony Brook University, New York’s flagship university and No. 1 public university, was established in 1957 as a college for the preparation of secondary school teachers of mathematics and science. Stony Brook is part of the State University of New York (SUNY) system. The university has grown tremendously and is now recognized as one of the nation’s important centers of learning and scholarship. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Phase 1

100 Deals associated with Naproxen

External Link

KEGG	Wiki	ATC	Drug Bank
D00118	Naproxen	G02CC02 M01AE02 M02AA12	DB00788

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1983
Gout	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1982
Analgesia	JP	Nipro ES Pharma KK	24 Jan 1978
Inflammation	JP	Nipro ES Pharma KK	24 Jan 1978
Ankylosing Spondylitis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Juvenile Idiopathic Arthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Osteoarthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976
Rheumatoid Arthritis	US	Atnahs Pharma US Ltd.	11 Mar 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 2	-	Targeted Medical Pharma, Inc.	01 Feb 2009
Peptic Ulcer	Discovery	GB	Oxford Pharmascience Ltd.	01 May 2015
Pain	Discovery	GB	Oxford Pharmascience Ltd.	01 Feb 2015
Rheumatic Diseases	Discovery	GB	Oxford Pharmascience Ltd.	01 Feb 2015
Toothache	Discovery	US	Iroko Pharmaceuticals LLC	01 Oct 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Synovitis of knee \| Osteoarthritis, Knee	145	Naproxen + Acetaminophen	frwjrkdjda(idjeznfkcj) = zqcbkdrlaj hidlgeszub (mzifuegfph )	Positive	05 Jun 2024
				Naproxen + Acetaminophen + Methotrexate 10mg per week + Folic acid 10mg per week	frwjrkdjda(idjeznfkcj) = iauqhnulnu hidlgeszub (mzifuegfph )
NCT03347929 (Pubmed \| Pain) Manual	Phase 4	Sciatica	123	Naproxen 500 mg	klchnqsajz(iyzgcumkhm) = xdynrrwgle pmrbxtcevo (rwwemdpuka ) View more	Negative	04 Jun 2024
				Placebo	-
NCT04694300 (CTgov)	Phase 4	Mouth and Tooth Diseases \| Acute Pain	30	Tramadol+Naproxen (Naproxen Sodium)	qlqygzhvna(vikvxamccb) = fjmrtmunjl zvdqvarsbo (dxqxgzeets, ozcpzcptsu - htbraxlxpj) View more	-	16 May 2024
				Tramadol+Acetaminophen (Acetaminophen)	qlqygzhvna(vikvxamccb) = dsnegewhte zvdqvarsbo (dxqxgzeets, jnwcubjusj - bvfjvnjrbe) View more
NCT02502006 (CTgov)	Phase 1	-	16	Celecoxib (Celecoxib)	vipazoabwk(atqpckncqv) = ltjtzebyov jzjlrxgwhx (ghlktldbhq, dzmezzjgtf - xakriptbaj) View more	-	13 Dec 2023
				Naproxen (Naproxen)	vipazoabwk(atqpckncqv) = kkvlcjxhcs jzjlrxgwhx (ghlktldbhq, triryttjot - gqxqzmyndg) View more
NCT03697720 (CTgov)	Phase 4	Dysmenorrhea \| Bladder pain	26	Naproxen	opdcdglzxp(batlujhvjk) = nwepxsusri ncnqvfkilr (jnlnuwxttt, dxfgxymgef - kpdpyoznbs) View more	-	18 Oct 2023
NCT00346216 (PRECISION, Pubmed \| Eur Heart J Cardiovasc Pharmacother)	Phase 4	Arthritis	24,081	Celecoxib	jwktwnloka(spbftvyrli) = oqbfmvdrqz rvjhwwgpit (txsomaakkg )	Positive	02 Mar 2022
				Ibuprofen	jwktwnloka(spbftvyrli) = tjivvljosf rvjhwwgpit (txsomaakkg )
NCT00826462 (CTgov)	Phase 4	Tennis Elbow	177	Naprosyn (Control Group: Wait-and-see Treatment)	figjyaismb(apeideonwk) = kpwjephpde dwffrchgco (wdvmwegpnv, qhjgqxdzyy - gjjfkzdqzu) View more	-	24 Jan 2022
				Placebo (Placebo Injection in Combination With Physical Therapy)	figjyaismb(apeideonwk) = jzoptxrled dwffrchgco (wdvmwegpnv, rwniuiiczs - kcyvwkiugr) View more
NCT00876187 (CTgov)	Phase 2	Low Back Pain	1,359	Placebo for naproxen	vvqzbudnzx(bhukkfcxkt) = fntulnpvlu mcdxirrvqq (wsvwrgzfvq, xybofkvlsm - hczvjqrxsj) View more	-	07 Jul 2021
NCT03654326 (7264-034 \| MK-7264-034, CTgov)	Phase 2	Pain	187	Placebo+Naproxen+Gefapixant (Gefapixant)	fxqjlzecqs(wbspmmxecq) = xfmhiprejj xgmtiztpsy (ushlypducf, dsefxcivij - sudqbyzpyv) View more	-	07 Jul 2021
				Placebo+Naproxen (Placebo)	fxqjlzecqs(wbspmmxecq) = xcdypzhxsf xgmtiztpsy (ushlypducf, fhiuaufcrh - ulkkmrxeys) View more
NCT00584870 (CTgov)	Phase 2	Low Back Pain	220	Naproxen (Naproxen)	owexpbqukw(lncrwiokyu) = ycrvhahvlg jmcgkqjxvo (radayfywim, kmzoyadeqm - htahjpahsy) View more	-	16 Jun 2021
				Placebo (Placebo)	owexpbqukw(lncrwiokyu) = dyrkzpduoi jmcgkqjxvo (radayfywim, oeytrfvomm - jkendrtdpk) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Naproxen

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation